Theralase Technologies (CVE:TLT) Trading 2.4% Higher - Here's Why

Key Points

• Theralase Technologies Inc. shares rose by 2.4% to C$0.22, despite a significant drop in trading volume to 11,505 shares, down 88% from the average.
• The company has a market capitalization of C$52.35 million, a quick ratio of 3.40, and a notable debt-to-equity ratio of 14.85.
• Theralase focuses on the research and development of light activated photo dynamic compounds for treating cancers, bacteria, and viruses, as well as patented laser technology for pain relief.

Shares of Theralase Technologies Inc. (CVE:TLT - ) traded up 2.4% on Tuesday . The stock traded as high as C$0.23 and last traded at C$0.22. 11,505 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 94,024 shares. The stock had previously closed at C$0.21.

Theralase Technologies Trading Up 2.4%

The company has a quick ratio of 3.40, a current ratio of 1.91 and a debt-to-equity ratio of 14.85. The firm's 50-day simple moving average is C$0.20 and its 200 day simple moving average is C$0.21. The stock has a market capitalization of C$52.35 million, a P/E ratio of -11.45 and a beta of 1.36.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.